| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
a Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA; b Center for NeuroOncology, Dana Farber/Brigham and Womens Cancer Center, Boston, Massachusetts, USA
Key Words. Angiogenesis inhibitors • Glioblastoma multiforme • Targeted therapy • Tyrosine kinase inhibitors
David A. Reardon, M.D., Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, DUMC 3624, Durham, North Carolina 27710, USA. Telephone: 919-684-3457; Fax: 919-684-6674; e-mail: reard003{at}mc.duke.edu and Patrick Y. Wen, M.D., Center for NeuroOncology, Dana Farber/Brigham and Womens Cancer Center, 44 Binney Street, Boston, Massachusetts 02115, USA. Telephone: 617-632-2166; Fax: 617-632-4773; e-mail: patrick_wen{at}dfci.harvard.edu
Despite advances in standard therapy, including surgical resection followed by radiation and chemotherapy, the prognosis for patients with glioblastoma multiforme (GBM) remains poor. Unfortunately, most patients die within 2 years of diagnosis of their disease. Molecular abnormalities vary among individual patients and also within each tumor. Indeed, one of the distinguishing features of GBM is its marked genetic heterogeneity. Nonetheless, recent developments in the field of tumor biology have elucidated signaling pathways and genes involved in the development of GBM, and several novel agents that target these signaling pathways are being developed. As new details on the genetic characteristics of this disease become available, innovative treatment regimens, including a variety of traditional treatment modalities such as surgery, radiation, and cytotoxic chemotherapy, will be combined with newer targeted therapies. This review introduces these new targeted therapies in the context of current treatment options for patients with GBM. It is hoped that this combined approach will overcome the current limitations in the treatment of patients with GBM and result in a better prognosis for these patients.
This article has been cited by other articles:
![]() |
M. Diehn, C. Nardini, D. S. Wang, S. McGovern, M. Jayaraman, Y. Liang, K. Aldape, S. Cha, and M. D. Kuo From the Cover: Identification of noninvasive imaging surrogates for brain tumor gene-expression modules PNAS, April 1, 2008; 105(13): 5213 - 5218. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Lefranc, V. Facchini, and R. Kiss Proautophagic Drugs: A Novel Means to Combat Apoptosis-Resistant Cancers, with a Special Emphasis on Glioblastomas Oncologist, December 1, 2007; 12(12): 1395 - 1403. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Brown and A. Law Morphoproteomic Demonstration of Constitutive Nuclear Factor-kappaB Activation in Glioblastoma Multiforme with Genomic Correlates and Therapeutic Implications Ann. Clin. Lab. Sci., January 1, 2006; 36(4): 421 - 426. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |